Reckitt to discontinue Suboxone tablets in U.S.

September 27, 2012

LONDON (Reuters) – British consumer goods group Reckitt Benckiser is to withdraw its Suboxone heroin treatment tablets in favor of a film version in the United States over the next six months due to the higher risk of children getting hold of the tablets. (Source: Reuters: Health)

Read the full article →

Reckitt withdraws Suboxone over abuse

September 27, 2012

Opioid dependency treatment, a legacy product for the household and personal care company, voluntarily withdrawn in US over increasing signs of abuse of the medicine (Source: FT.com – Drugs and Healthcare)

Read the full article →

Reckitt withdraws Suboxone over abuse

September 27, 2012

Opioid dependency treatment, a legacy product for the household and personal care company, voluntarily withdrawn in US over increasing signs of abuse of the medicine (Source: FT.com – Drugs and Healthcare)

Read the full article →

Reckitt withdraws Suboxone over abuse

September 27, 2012

Opioid dependency treatment, a legacy product for the household and personal care company, voluntarily withdrawn in US over increasing signs of abuse of the medicine (Source: FT.com – Drugs and Healthcare)

Read the full article →

Reckitt withdraws Suboxone over abuse

September 27, 2012

Opioid dependency treatment, a legacy product for the household and personal care company, voluntarily withdrawn in US over increasing signs of abuse of the medicine (Source: FT.com – Drugs and Healthcare)

Read the full article →

Suboxone Maker Pulls Pills in Favor of Film

September 27, 2012

(MedPage Today) — The buprenorphine-naloxone combination product (Suboxone) in sublingual tablet form will soon be pulled from the U.S. market because its child-resistant packaging isn’t effective enough. (Source: MedPage Today Psychiatry) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Read the full article →

Suboxone Maker Pulls Pills in Favor of Film

September 27, 2012

(MedPage Today) — The buprenorphine-naloxone combination product (Suboxone) in sublingual tablet form will soon be pulled from the U.S. market because its child-resistant packaging isn’t effective enough. (Source: MedPage Today Psychiatry) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Read the full article →

Suboxone Maker Pulls Pills in Favor of Film

September 27, 2012

(MedPage Today) — The buprenorphine-naloxone combination product (Suboxone) in sublingual tablet form will soon be pulled from the U.S. market because its child-resistant packaging isn’t effective enough. (Source: MedPage Today Psychiatry) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Read the full article →

Suboxone Maker Pulls Pills in Favor of Film

September 27, 2012

(MedPage Today) — The buprenorphine-naloxone combination product (Suboxone) in sublingual tablet form will soon be pulled from the U.S. market because its child-resistant packaging isn’t effective enough. (Source: MedPage Today Psychiatry) MedWorm Sponsor Message: Have a look at The Addiction Daily, the new MedWorm portal, updated daily with all the latest addiction news and research.

Read the full article →

When the rubber meets the road: Predicting how parity will affect access to substance abuse services and costs

September 26, 2012

This presentation will discuss the likely impacts of Mental Health Parity and Addiction Equity Act on substance abuse treatment services use and costs based on an analysis of health insurance claims and health insurance booklets. The data are from approximately 100 large, self-insured employers and millions of enrollees covering the period 2001–2009. Among the findings […]

Read the full article →

← Previous Entries

Next Entries →